Table 3.
Demographic and comorbidity characteristics of episodes that ended in stroke by allopurinol use
| Episodes with stroke | P-value | ||
|---|---|---|---|
| Not on Allopurinol (NE = 843) |
On Allopurinol (NE = 1,334) |
||
| Age | 77.5 (7.1) | 78.5 (7.4) | 0.003 |
| Gender | 0.95 | ||
| Male | 378 (44.8) | 600 (45.0) | |
| Female | 465 (55.2) | 734 (55.0) | |
| Race | 0.54 | ||
| White | 632 (75.0) | 1,025 (76.8) | |
| Black | 128 (15.2) | 194 (14.5) | |
| Others | 83 (9.9) | 115 (8.6) | |
| Charlson-Romano Index Score | 3.99 (3.27) | 4.44 (3.44) | 0.002 |
| Specific Comorbidities | |||
| Diabetes | 382 (45.3) | 641 (48.1) | 0.21 |
| Hypertension | 724 (85.9) | 1,174 (88.0) | 0.15 |
| Cardiovascular Disease | 128 (15.2) | 232 (17.4) | 0.18 |
| Peripheral Vascular Disease | 187 (22.2) | 302 (22.6) | 0.80 |
| Hyperlipidemia | 591 (70.1) | 970 (72.7) | 0.19 |
NE number of episodes